Statistics for Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective
Total visits
| views | |
|---|---|
| Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective | 17 |
Total visits per month
| views | |
|---|---|
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
Top country views
| views | |
|---|---|
| Portugal | 14 |
| United States | 5 |
| China | 1 |
| Colombia | 1 |
| United Kingdom | 1 |
Top city views
| views | |
|---|---|
| Los Angeles | 5 |